GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » aTyr Pharma Inc (NAS:LIFE) » Definitions » Cyclically Adjusted Price-to-FCF

aTyr Pharma (aTyr Pharma) Cyclically Adjusted Price-to-FCF : (As of May. 04, 2024)


View and export this data going back to 2015. Start your Free Trial

What is aTyr Pharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


aTyr Pharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for aTyr Pharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

aTyr Pharma Cyclically Adjusted Price-to-FCF Chart

aTyr Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

aTyr Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of aTyr Pharma's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, aTyr Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


aTyr Pharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, aTyr Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where aTyr Pharma's Cyclically Adjusted Price-to-FCF falls into.



aTyr Pharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

aTyr Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, aTyr Pharma's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.187/129.4194*129.4194
=-0.187

Current CPI (Dec. 2023) = 129.4194.

aTyr Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -9.106 99.695 -11.821
201406 -6.858 100.560 -8.826
201409 -8.025 100.428 -10.342
201412 -8.057 99.070 -10.525
201503 -3.978 99.621 -5.168
201506 -10.572 100.684 -13.589
201509 -5.849 100.392 -7.540
201512 -5.883 99.792 -7.630
201603 -7.586 100.470 -9.772
201606 -8.376 101.688 -10.660
201609 -8.713 101.861 -11.070
201612 -6.931 101.863 -8.806
201703 -8.343 102.862 -10.497
201706 -5.717 103.349 -7.159
201709 -5.062 104.136 -6.291
201712 -4.895 104.011 -6.091
201803 -5.204 105.290 -6.397
201806 -4.329 106.317 -5.270
201809 -3.043 106.507 -3.698
201812 -2.235 105.998 -2.729
201903 -2.494 107.251 -3.010
201906 -1.486 108.070 -1.780
201909 -1.113 108.329 -1.330
201912 -1.272 108.420 -1.518
202003 0.275 108.902 0.327
202006 -0.686 108.767 -0.816
202009 -0.577 109.815 -0.680
202012 -0.503 109.897 -0.592
202103 -0.414 111.754 -0.479
202106 -0.483 114.631 -0.545
202109 -0.635 115.734 -0.710
202112 -0.291 117.630 -0.320
202203 -0.365 121.301 -0.389
202206 -0.327 125.017 -0.339
202209 -0.443 125.227 -0.458
202212 -0.394 125.222 -0.407
202303 -0.044 127.348 -0.045
202306 -0.261 128.729 -0.262
202309 -0.175 129.860 -0.174
202312 -0.187 129.419 -0.187

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


aTyr Pharma  (NAS:LIFE) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


aTyr Pharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of aTyr Pharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


aTyr Pharma (aTyr Pharma) Business Description

Industry
Traded in Other Exchanges
Address
10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Executives
Sanjay Shukla officer: Chief Medical Officer C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO CA 92121
Paul Schimmel director 88 SIDNEY ST, CAMBRIDGE MA 02139
Jill Marie Broadfoot officer: Chief Financial Officer 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Sara Zaknoen director C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
John K Clarke director C/O CARDINAL HEALTH PARTNERS, 221 NASSAU STREET, PRINCETON NJ 08542
Nancy Krueger officer: See Remarks C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Svetlana Lucas director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
John Mendlein director, officer: CEO and Executive Chairman
Ecor1 Capital Fund Qualified, L.p. 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ashraf Amanullah officer: Vice President, Manufacturing C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
John T Blake officer: Vice President, Finance C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342
Timothy P Coughlin director 339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Jeffrey S. Hatfield director 11080 ROSELLE STREET, SAN DIEGO CA 92121
David John King officer: See Remarks 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121

aTyr Pharma (aTyr Pharma) Headlines

From GuruFocus

aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference

By sperokesalga sperokesalga 05-25-2023